Product Description
For Type 2 Diabetes (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02445911)
Mechanisms of Action: PTP1B Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kaneq Bioscience Limited
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Insulin Resistance|Type 2 Diabetes
Recent News Events
Date |
Type |
Title |
|---|